TOP > クイック検索 > 外国特許検索 > IMMUNE FUNCTION INSPECTION METHOD, CANCER PATIENT CATEGORIZATION METHOD, CANCER TREATMENT EFFICACY PREDICTION METHOD, AGENT FOR INCREASING INTRACELLULAR CALCIUM ION CONCENTRATION, AGENT FOR INCREASING SELECTIVE FUNCTION OF EFFECTOR MEMORY (EM) AND EFFECTOR (EFF) IN TUMOR TISSUE, AND METHOD FOR MONITORING EFFICACY OF CANCER DRUG

IMMUNE FUNCTION INSPECTION METHOD, CANCER PATIENT CATEGORIZATION METHOD, CANCER TREATMENT EFFICACY PREDICTION METHOD, AGENT FOR INCREASING INTRACELLULAR CALCIUM ION CONCENTRATION, AGENT FOR INCREASING SELECTIVE FUNCTION OF EFFECTOR MEMORY (EM) AND EFFECTOR (EFF) IN TUMOR TISSUE, AND METHOD FOR MONITORING EFFICACY OF CANCER DRUG UPDATE

外国特許コード F170009152
整理番号 (S2016-0384-N0)
掲載日 2017年8月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP005011
国際公開番号 WO 2017138660
国際出願日 平成29年2月10日(2017.2.10)
国際公開日 平成29年8月17日(2017.8.17)
優先権データ
  • 特願2016-024363 (2016.2.12) JP
  • 特願2016-204284 (2016.10.18) JP
発明の名称 (英語) IMMUNE FUNCTION INSPECTION METHOD, CANCER PATIENT CATEGORIZATION METHOD, CANCER TREATMENT EFFICACY PREDICTION METHOD, AGENT FOR INCREASING INTRACELLULAR CALCIUM ION CONCENTRATION, AGENT FOR INCREASING SELECTIVE FUNCTION OF EFFECTOR MEMORY (EM) AND EFFECTOR (EFF) IN TUMOR TISSUE, AND METHOD FOR MONITORING EFFICACY OF CANCER DRUG UPDATE
発明の概要(英語) The present invention pertains to an immune function inspection method in which peripheral blood is collected from a human subject, changes in the concentration of calcium ions in peripheral blood mononuclear cells (PBMC) or CD8T cells are inspected after application of an immunostimulant, and if, after the application of the immunostimulant, there is a transient increase in the concentration of calcium ions in the PBMC or CD8T cells and then the concentration returns to the pre-stimulated state, it is determined that there is a decrease in systemic immune function, and if, after the application of the immunostimulant, there is an upward trend in the concentration of calcium ions in the PBMC or CD8T cells, it is determined that the systemic immune function is normal.
特許請求の範囲(英語) [claim1]
1. It extracts the peripheral blood of the human subject, after the applying, peripheral blood single nuclear sphere (PBMC) or change of calcium ion concentration inside the CD8T cell is inspected, after the applying the immunity stimulant calcium ion concentration inside the PBMC or CD8T cell rises in temporariness, it judges the immunity stimulant, that after that immunity function of the entire body has decreased to the case where it returns to the state before the stimulating, immunity function of the entire body is judged when after the applying the immunity stimulant calcium ion concentration inside the PBMC or CD8T cell is in rise keynote, that it is normal, inspection of immunity functionMethod.
[claim2]
2. At least 1 where it is chosen from the group which at least does the combined use medical therapy of 1 where it is chosen from the group which consists of huenhorumin, buhorumin and metohorumin vis-a-vis the cancer patient who is judged that immunity function of the entire body has decreased with inspection method of claim 1, kinds and the other cancer remedy, consists of huenhorumin, buhorumin and metohorumin kinds and selective method of the cancer patient who applies the combined use medical therapy of the other cancer remedy.
[claim3]
3. The other cancer remedy, the anti- PD-1 antibody, aspirin, the star chin, is curcumine, berberine, the royal jello or the professional polis, in claim 2 selective method of the patient of statement.
[claim4]
4. The method at least of estimating 1 where it is chosen from the group which includes the below-mentioned process (1)-(2), consists of huenhorumin, buhorumin and metohorumin kinds and the curative effect for the cancer patient of combined use medical therapy of the other cancer remedy:
When (1) the single nuclear sphere which is included in the peripheral blood which was picked from the cancer patient (PBMC) immunity stimulating, the process which is appraised whether calcium ion concentration inside the cell rises in temporariness, or rises continuously, and
When (2) after calcium ion concentration inside the cell of PBMC at the time of immunity stimulus rose in temporariness, it falls rapidly, the process which it estimates that the possibility at least combined use medical therapy of 1 where it is chosen from the group which consists of huenhorumin, buhorumin and metohorumin kinds and the other cancer remedy showing the curative effect is high.
[claim5]
5. The below-mentioned process (1)-(2) is included, remedy method of the cancer patient:
When (1) the single nuclear sphere which is included in the peripheral blood which was picked from the cancer patient (PBMC) immunity stimulating, the process which is appraised whether calcium ion concentration inside the cell rises in temporariness, or rises continuously,
When (2) after calcium ion concentration inside the cell of PBMC at the time of immunity stimulus rose in temporariness, it falls rapidly, the process which it estimates that the possibility at least combined use medical therapy of 1 where it is chosen from the group which consists of huenhorumin, buhorumin and metohorumin kinds and the other cancer remedy showing the curative effect is high, and
In the patient whom it estimates that the possibility of showing the curative effect (3) in process (2) is high, at least 1 where it is chosen from the group which consists of huenhorumin, buhorumin and metohorumin kinds and the process which prescribes the other cancer remedy.
[claim6]
6. 1 where it is chosen from the group which consists of huenhorumin, buhorumin and metohorumin kinds are included at least, the calcium ion concentration rise medicine inside the cell of the CD8T cell by immunity stimulus.
[claim7]
7. Calcium ion concentration inside the cell of the CD8T cell which is while tumor organizing is risen selectively, the calcium ion concentration rise medicine inside the cell of the CD8T cell by the immunity stimulus of statement in claim 6.
[claim8]
8. The ehuekuta memory which includes 1 where it is chosen from the group which consists of huenhorumin, buhorumin and metohorumin kinds at least, in tumor organizing (EM) with ehuekuta (eff) the selective functional improver.
[claim9]
9. 1 where it is chosen from the group which consists of huenhorumin, buhorumin and metohorumin kinds are included at least, the cancer remedy which is prescribed to the cancer patient where the glucose density which is while tumor organizing is 0.5-1.5mM.
[claim10]
10. Process 1 below) - process 3) it includes, monitoring method of the effect of the cancer remedy:
Process 1) The process which separates the lymphocyte inside the tumor from cancer organization,
Process 2) The glucose trance porter of the tumor infiltration lymphocyte which is separated (Glut1) the process which analyzes revelation level,
Process 3) Whether or not the cancer remedy which has been prescribed already to the cancer patient on the basis of the revelation level of Glut1 which was analyzed, validity decision/the process which is appraised
(Here, cancer organization the cancer remedy after the prescribing is something which is extracted from the cancer patient.).
[claim11]
11. The cancer remedy, the cancer vaccine, the immunity checkpoint obstruction medicine, is chosen from the group which consists of huenhorumin, buhorumin and metohorumin, in claim 9 monitoring method of the effect of the cancer remedy of statement.
[claim12]
12. Glut1 revelation level is analyzed with flow sight meter, in claim 10 or 11 monitoring method of the effect of the cancer remedy of statement.
[claim13]
13. The tumor infiltration lymphocyte is the CD8T cell, either of the claim 10-12 in 1 sections monitoring method of the effect of the cancer remedy of statement.
[claim14]
14. Process 3, cultures the tumor infiltration lymphocyte which is separated in the nutrient medium of glucose density of 2 hours or more, and above 0.1mM after that the glucose trance porter (Glut1) analyzes revelation level, either of the claim 10-13 in 1 sections monitoring method of the effect of the cancer remedy of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OKAYAMA UNIVERSITY
  • 発明者(英語)
  • UDONO HEIICHIRO
  • EIKAWA SHINGO
国際特許分類(IPC)
指定国 (WO2017138660)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close